3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Cholangiocarcinoma
6
Gastrointestinal Neoplasms
3
Carcinoma, Transitional Cell
3
Breast Neoplasms
3
Pancreatic Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Solid Tumor, Miscellaneous
1
Solid Tumor
1
Sarcoma
1
Recurrence
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Locally Advanced Unresectable Gastric Cancer
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Gastrointestinal Stromal Tumors
1
Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel
1
Digestive System Neoplasms
1
Advanced Non-Small Cell Lung Cancer
1
Advanced Non Small Cell Lung Cancer
1
Interventions
pemigatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Solid Tumor, Miscellaneous
×
pemigatinib
×
Clear all
NCT06653777
2025-06-05
AcSé PEMI
UNICANCER
Phase 2
Recruiting
40 enrolled